Clinical trial
A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM)
NCT05211154 is registered in ClinicalTrials.gov with Danish Headache Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM)
- Lead sponsor
- Danish Headache Center
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- May 5, 2022
- Completion date
- April 30, 2025
- Enrollment
- 300 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.